AM-279

AM-279 is a synthetic compound that is part of the Aminoalkylindole family. It is known for its potential therapeutic uses, particularly in the field of neuroscience and pharmacology.

History

AM-279 was first synthesized in the late 20th century as part of a series of experiments aimed at discovering new cannabinoid receptor agonists. These experiments were conducted by a team of scientists led by Alexandros Makriyannis, a renowned chemist and professor at the Northeastern University in Boston, Massachusetts.

Chemical Structure

AM-279 is a derivative of the indole class of compounds. It is characterized by a unique chemical structure that includes a naphthoyl group attached to the indole ring via a methylene bridge. This structure is believed to be responsible for the compound's high affinity for the cannabinoid receptors.

Pharmacology

AM-279 acts as a potent and selective agonist for the CB1 receptor, one of the two main types of cannabinoid receptors in the body. It has been shown to produce a range of effects similar to those of tetrahydrocannabinol (THC), the main psychoactive component of cannabis. These effects include analgesia, anti-emesis, and appetite stimulation, among others.

Potential Therapeutic Uses

Due to its pharmacological properties, AM-279 has been studied for potential therapeutic uses. Some of these include the treatment of chronic pain, nausea and vomiting associated with chemotherapy, and anorexia related to AIDS or cancer. However, more research is needed to fully understand the potential benefits and risks of this compound.

See Also

• Cannabinoid receptor
• Aminoalkylindole
• Alexandros Makriyannis
• CB1 receptor
• Tetrahydrocannabinol